Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First Clinical Trial of AT-001 (NPI-001) for the Treatment of HCCAA
March 12, 2024 09:00 ET
|
Nacuity Pharmaceuticals, Inc.
REYKJAVIK, Iceland and FORT WORTH, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Arctic Therapeutics ehf, an Icelandic drug development company and partner Nacuity Pharmaceuticals, Inc., a...
Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease
November 03, 2023 12:00 ET
|
Alkeus Pharmaceuticals
Primary endpoint met, demonstrating a 21% slowing (p<0.001) in the growth rate of atrophic retinal lesions compared to the untreated arm; 28% reduction (p<0.001) using observed atrophic...
Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron’s REVeRT technology
October 25, 2023 08:00 ET
|
ViGeneron GmbH
REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packaging size in various tissuesPotential to address prevalent inherited diseases...
Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome
May 31, 2023 09:00 ET
|
Nacuity Pharmaceuticals, Inc.
Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with USH Interim efficacy data anticipated by year end 2023 FORT WORTH, Texas, May 31, 2023 (GLOBE...
Leber Congenital Amaurosis Market Is Estimated to Grow at CAGR Of 4.8%, 2022-2029 | Latest Industry Coverage by Douglas Insights
January 20, 2023 01:23 ET
|
Douglas Insights
Douglas, Jan. 20, 2023 (GLOBE NEWSWIRE) -- The Leber Congenital Amaurosis Market Report by Douglas Insights aims to inform about the details of growing developments, market share, and any localized...
ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target
April 06, 2022 03:00 ET
|
ViGeneron GmbH
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy productViGeneron is...
FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 (C20-D3-vitamin A) for the Treatment of Stargardt Disease
July 14, 2021 07:00 ET
|
Alkeus Pharmaceuticals
Only drug to receive Breakthrough Therapy Designation for Stargardt DiseaseAlkeus Pharmaceuticals to discuss next steps toward filing an NDA with the FDAOngoing clinical trial of ALK-001 in dry...